home / stock / ctrv / ctrv quote
Last: | $ |
---|---|
Change Percent: | 0.56% |
Open: | $3.59 |
Close: | $3.58 |
High: | $3.70 |
Low: | $3.53 |
Volume: | 138,468 |
Last Trade Date Time: | 07/22/2019 04:54:14 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $3.59 | $3.58 | $3.70 | $3.53 | 138,468 | 07-22-2019 |
$ | $3.59 | $3.56 | $3.6697 | $3.56 | 109,605 | 07-19-2019 |
$ | $3.66 | $3.62 | $3.7995 | $3.57 | 137,209 | 07-18-2019 |
$ | $3.68 | $3.65 | $3.98 | $3.65 | 295,716 | 07-17-2019 |
$ | $3.89 | $3.75 | $3.9242 | $3.65 | 212,557 | 07-16-2019 |
$ | $3.95 | $3.92 | $4.15 | $3.861 | 152,612 | 07-15-2019 |
$ | $3.98 | $4.01 | $4.25 | $3.95 | 614,025 | 07-12-2019 |
$ | $4.12 | $4.04 | $4.15 | $3.8392 | 271,327 | 07-11-2019 |
$ | $3.76 | $4.12 | $4.45 | $3.62 | 1,734,730 | 07-10-2019 |
$ | $3.80 | $3.74 | $3.97 | $3.706 | 229,752 | 07-09-2019 |
$ | $3.81 | $3.86 | $4.0764 | $3.80 | 220,843 | 07-08-2019 |
$ | $3.53 | $3.87 | $4.104 | $3.52 | 737,082 | 07-05-2019 |
$ | $3.70 | $3.64 | $3.87 | $3.5503 | 298,368 | 07-04-2019 |
$ | $3.70 | $3.64 | $3.87 | $3.5503 | 298,368 | 07-03-2019 |
$ | $3.97 | $3.73 | $3.99 | $3.63 | 659,638 | 07-02-2019 |
$ | $4.07 | $4.00 | $4.22 | $3.9195 | 352,077 | 07-01-2019 |
$ | $4.13 | $4.17 | $4.37 | $4.03 | 438,458 | 06-28-2019 |
$ | $4.18 | $4.22 | $4.34 | $4.03 | 597,810 | 06-27-2019 |
$ | $4.50 | $4.14 | $4.5811 | $4.05 | 809,239 | 06-26-2019 |
$ | $4.82 | $4.58 | $4.882 | $4.54 | 574,832 | 06-25-2019 |
News, Short Squeeze, Breakout and More Instantly...
ContraVir Pharmaceuticals Inc. Company Name:
CTRV Stock Symbol:
NASDAQ Market:
ContraVir Pharmaceuticals Inc. Website:
EDISON, N.J., July 22, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral i...
ContraVir Pharmaceuticals (NASDAQ: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, has closed an underwritten public offering res...
EDISON, N.J., June 27, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral i...